Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Payables (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Payables for 6 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Payables fell 70.99% to $1.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.2 million, a 70.99% decrease, with the full-year FY2025 number at $1.2 million, down 70.99% from a year prior.
  • Payables was $1.2 million for Q4 2025 at TScan Therapeutics, down from $6.4 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $6.4 million in Q3 2025 to a low of $1.2 million in Q4 2025.
  • A 5-year average of $3.4 million and a median of $3.1 million in 2024 define the central range for Payables.
  • Biggest YoY gain for Payables was 133.91% in 2025; the steepest drop was 70.99% in 2025.
  • TScan Therapeutics' Payables stood at $1.8 million in 2021, then skyrocketed by 64.99% to $2.9 million in 2022, then decreased by 18.48% to $2.4 million in 2023, then soared by 80.2% to $4.3 million in 2024, then crashed by 70.99% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for TCRX's Payables are $1.2 million (Q4 2025), $6.4 million (Q3 2025), and $4.5 million (Q2 2025).